NCT00397046View on ClinicalTrials.gov

A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

Tumors

Interventions

DRUG

neratinib

HKI-272

Trial Locations (2)

135-8550

The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto

1411-8777

Shizuoka Cancer Center, Shizuoka

All Listed Sponsors

lead

Puma Biotechnology, Inc.

INDUSTRY

NCT00397046 - A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter